Dry Eye Disease: Causes, Symptoms, Diagnosis, and Evidence-Based Treatment

Dry eye disease (DED) is a multifactorial disorder of the tear film and ocular surface characterized by loss of homeostasis, tear film instability, hyperosmolarity, inflammation, and neurosensory abnormalities. It affects 5–50% of adults, increasing with age and female sex.

Pathophysiology: Two Main Mechanisms (Often Coexist)

  • Aqueous-Deficient DED: Reduced lacrimal secretion. Causes: Sjögren syndrome (primary/secondary), age-related lacrimal dysfunction, medications (anticholinergics, antihistamines, beta-blockers, isotretinoin), graft-versus-host disease, radiation, lacrimal gland infiltration.
  • Evaporative DED: Excessive tear evaporation due to meibomian gland dysfunction (MGD) — the leading cause (>80% of DED). MGD: terminal duct obstruction, qualitative/quantitative meibum alteration. Contributors: rosacea, Demodex, contact lens wear, blink abnormalities, preservatives in eyedrops.

Risk Factors

  • Age >50, female sex (hormonal), menopause
  • Environmental: low humidity, wind, air conditioning, screen use (reduced blink rate)
  • Systemic: autoimmune (RA, SLE, Sjögren), diabetes, thyroid disease
  • Medications: antihistamines, antidepressants, diuretics, isotretinoin, hormone therapy
  • Ocular surgery: LASIK (corneal nerve damage), cataract surgery
  • Contact lens wear

Symptoms

  • Foreign body sensation, grittiness, burning, stinging
  • Paradoxical tearing (reflex)
  • Blurred vision fluctuating with blink
  • Light sensitivity, eye fatigue
  • Contact lens intolerance
  • Symptoms worse late day (evaporative) or morning (nocturnal lagophthalmos)

Diagnosis (TFOS DEWS II Framework)

  • Screening: Symptom questionnaires (OSDI, SPEED, DEQ-5)
  • Signs: Tear film break-up time (TBUT <10s), Schirmer test (<5mm/5min aqueous deficiency), ocular surface staining (fluorescein, lissamine green), meibography (gland dropout), tear osmolarity (>308 mOsm/L or inter-eye difference >8), MMP-9 positivity (InflammaDry).

Stepwise Management (TFOS DEWS II / AAO Guidelines)

Step 1: Education & Environmental Modification

  • Hydration, humidifier, screen breaks (20-20-20 rule), omega-3 supplementation, smoking cessation
  • Lid hygiene: warm compresses (10 min, 40°C), lid scrubs (hypochlorous acid, tea tree oil for Demodex)

Step 2: Artificial Tears & Topical Therapy

  • Preservative-free artificial tears (carboxymethylcellulose, hyaluronic acid, lipid-based for MGD)
  • Gels/ointments at bedtime
  • Topical cyclosporine 0.05% (Restasis) or 0.09% (Cequa) — immunomodulation
  • Lifitegrast 5% (Xiidra) — LFA-1 antagonist, reduces inflammation
  • Short-term topical steroid (loteprednol, fluorometholone) for flares
  • Varenicline nasal spray (Tyrvaya) — cholinergic agonist stimulating tear production

Step 3: Procedural & Advanced

  • Punctal plugs: Silicone (permanent) or collagen (dissolvable) — conserve tears; avoid if significant inflammation.
  • Thermal pulsation (LipiFlow, iLux, TearCare): Heat + expression for MGD.
  • Intense Pulsed Light (IPL): For rosacea-associated MGD; reduces inflammation, improves meibum quality.
  • Amniotic membrane graft: Severe surface disease, neurotrophic keratitis.
  • Autologous serum tears: 20–50% concentration — growth factors, vitamins.
  • Scleral lenses: Fluid reservoir protects cornea.

Step 4: Surgical (Refractory)

  • Punctal cautery (permanent occlusion)
  • Tarsorrhaphy (partial lid closure)
  • Salivary gland transplantation (severe Sjögren)

Special Populations

  • Sjögren Syndrome: Multidisciplinary care (rheumatology); systemic immunosuppressants (hydroxychloroquine, rituximab).
  • Post-LASIK: Usually transient (3–6 months); neurotrophic component.
  • Contact Lens Wearers: Daily disposables, silicone hydrogel, lens-free days.

Conclusion

DED is chronic and requires individualized, stepwise management. Addressing underlying MGD, inflammation, and environmental triggers improves outcomes. Regular follow-up and patient adherence are key.

Eye & Vision Disorders - Related Articles